Scorpius Holdings, Inc. (SCPX)
USD 0.15
(6.52%)
USD 0.15
(6.52%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -45.21 Million USD | -4.1% |
| 2022 | -43.43 Million USD | -23.85% |
| 2021 | -35.07 Million USD | -34.63% |
| 2020 | -26.04 Million USD | -30.13% |
| 2019 | -20.01 Million USD | -27.23% |
| 2018 | -15.73 Million USD | -32.87% |
| 2017 | -11.84 Million USD | 5.82% |
| 2016 | -12.57 Million USD | 38.04% |
| 2015 | -20.29 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -4.41 Million USD | 18.32% |
| 2024 Q2 | -8.87 Million USD | -100.9% |
| 2023 Q2 | -13.89 Million USD | -8.66% |
| 2023 Q3 | -13.13 Million USD | 5.47% |
| 2023 FY | -45.21 Million USD | -4.1% |
| 2023 Q1 | -12.78 Million USD | -5.21% |
| 2023 Q4 | -5.4 Million USD | 58.82% |
| 2022 Q2 | -10.15 Million USD | -25.08% |
| 2022 FY | -43.43 Million USD | -23.85% |
| 2022 Q4 | -12.15 Million USD | 6.57% |
| 2022 Q3 | -13 Million USD | -28.04% |
| 2022 Q1 | -8.12 Million USD | 40.13% |
| 2021 Q1 | -7.53 Million USD | 0.0% |
| 2021 FY | -35.07 Million USD | -34.63% |
| 2021 Q4 | -13.56 Million USD | -82.48% |
| 2021 Q3 | -7.43 Million USD | -13.59% |
| 2021 Q2 | -6.54 Million USD | 13.13% |
| 2020 FY | -26.04 Million USD | -30.13% |
| 2019 FY | -20.01 Million USD | -27.23% |
| 2018 FY | -15.73 Million USD | -32.87% |
| 2017 FY | -11.84 Million USD | 5.82% |
| 2016 FY | -12.57 Million USD | 38.04% |
| 2015 FY | -20.29 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | -56.126% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -423.832% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 34.511% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 7.376% |
| Azitra, Inc. | -11.28 Million USD | -300.727% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -492.313% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -512.633% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | -54.769% |
| CEL-SCI Corporation | -32.36 Million USD | -39.706% |
| iBio, Inc. | -24.9 Million USD | -81.544% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | -110.449% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | -128.682% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | -97.093% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -197.929% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -369.058% |
| NanoViricides, Inc. | -8.29 Million USD | -445.17% |
| Oragenics, Inc. | -20.65 Million USD | -118.909% |
| BiomX Inc. | -26.16 Million USD | -72.789% |
| BiomX Inc. | -26.16 Million USD | -72.789% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 643.999% |
| Palatin Technologies, Inc. | -29.73 Million USD | -52.061% |
| Theriva Biologics, Inc. | -18.34 Million USD | -146.429% |